Evolution of Respiratory Function in Lung Transplant Patients With Moderate to Severe Covid-19 Infection

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Jul 4, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how COVID-19 affects the breathing ability of lung transplant patients who have experienced moderate to severe infections. Researchers want to understand the differences in recovery between patients who were hospitalized but did not need intensive care and those who required more serious treatment, such as being put on a ventilator. The goal is to determine how the infection impacts their lung function over time and what factors might influence their recovery.

To participate in this study, individuals must be adult lung transplant patients who were diagnosed with COVID-19 between March 2020 and December 2022 and were treated at the University Hospitals of Strasbourg. Participants will be closely monitored to see how their respiratory health changes after the infection. It’s important to note that only patients who have not opted out of allowing their medical data to be used for research will be included. This study aims to provide valuable insights that could improve care for lung transplant patients facing COVID-19.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patient
• • Lung transplant patient (monopulmonary or bipulmonary)
• • Covid diagnosed by RT-PCR between March 1, 2020 and December 31, 2022
• • Hospitalization at the University Hospitals of Strasbourg for COVID-19
• • Patient followed in the context of their lung transplant at the University Hospitals of Strasbourg
• • Absence of written opposition in the subject's medical file to the reuse of their data for scientific research purposes.
• Exclusion Criteria:
• • Subject having expressed his opposition to the reuse of his data for scientific research purposes.